Not Yet RecruitingN/Aketamine

Outcomes Registry After Ketamine Infusions for Chronic Pain: A Longitudinal Evaluation

Sponsored by Stanford University

NCT ID
NCT07648771
Target Enrollment
800 participants
Start Date
2026-08
Est. Completion
2034-12

About This Study

Ketamine is an anesthetic drug that is sometimes used to relieve chronic pain. The goal of this observational study is to learn about how patients respond to ketamine infusions for chronic pain. Note: This study does not provide ketamine - instead, this study uses surveys to follow patients who are already scheduled to receive ketamine infusions as part of their regular medical care. We will also follow a second group of patients who were recommended ketamine infusions by their doctor but were denied insurance coverage for this treatment. These participants will complete the same surveys for up to 16 weeks, starting from when their treatment was originally scheduled. Comparing this group to patients who received ketamine will help researchers better understand ketamine's effects and how insurance denials affect chronic pain patients.

Conditions Studied

Chronic PainKetamine

Interventions

  • Ketamine (Ketalar)

Eligibility

Age:18 Years - N/A
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria:

* Planning to receive an intravenous ketamine infusion for the treatment of chronic pain

Exclusion Criteria:

* Unable to read or understand English questionnaires

Study Locations (1)

Stanford Health Care
Stanford, California, United States

Interested in this trial?

Contact the study team to learn more about eligibility and enrollment.

Protocol Director
CONTACT
650-264-9442tlii@stanford.edu
View on ClinicalTrials.gov
Data Source
ClinicalTrials.gov

Last updated from source